Skip to main content

Table 4 Cox proportional hazard regression analysis on the risk of mortality in patients received radiotherapy

From: Use of antipsychotic drugs during radiotherapy in adult cancer patients in Korea: a nationwide retrospective cohort study based on the national health insurance service database

Category

Incidence rate

Unadjusted

Adjusted

 

N

Case

Person years

Incidence

rate

HR (95% CI)

p-value

HR (95% CI)

p-value

During RT

Non APD

684,779

234,081

2781532.8

84.16

ref (1.00)

 

ref (1.00)

 

APD

41,118

33,854

49991.56

677.19

5.25 (5.19–5.31)

< 0.0001

3.58 (3.54–3.63)

< 0.0001

Psychiatric (-)a

12,454

11,050

12,855.87

859.53

ref (1.00)

 

ref (1.00)

 

Psychiatric (+)a

28,664

22,804

37,135.70

614.07

0.77(0.75–0.79)

< 0.0001

0.88(0.84–0.93)

< 0.0001

Deliriumb

1,749

1,451

1,943.18

746.71

ref (1.00)

 

ref (1.00)

 

Excluding deliriumb

26,945

21.353

38,048.38

606.75

0.93(0.88–0.98)

0.0093

0.90(0.85–0.96)

0.0005

Prescription Timea

    

Pre RT

12,655

7,725

20,526.42

376.34

ref (1.00)

 

ref (1.00)

 

During RT

28,463

20,224

23,147.42

873.70

1.84(1.79–1.89)

< 0.0001

1.32(1.27–1.37)

< 0.0001

Non after RT

24,789

27,949

49991.56

639.95

ref (1.00)

 

ref (1.00)

 

After RT

16,329

12,905

8,317.72

934.67

1.02(0.99–1.05)

0.3066

1.05(1.02–1.08)

0.0016

60 ~ 365days

10,0.979

8,786

6,894.84

773.47

ref (1.00)

 

ref (1.00)

 

> 365days

5,350

4,119

2,422.88

1,489.23

0.82(0.80–0.86)

< 0.0001

0.72(0.68–0.74)

< 0.0001

Prescription durationa

    

< 3 month

37,649

31,451

43,806.67

717.95

ref (1.00)

 

ref (1.00)

 

≥ 3 month

3,469

2,403

6,184.89

388.53

0.63 (0.6–0.65)

< 0.0001

0.80 (0.76–0.83)

< 0.0001

Prescription dosea

    

Low dose

36,140

29,905

42912.61

696.88

ref (1.00)

 

ref (1.00)

 

High dose

1,968

1,293

4302.05

300.55

0.6 (0.57–0.63)

< 0.0001

0.87 (0.82–0.92)

< 0.0001

During CCRT

Non APD

107,371

58,040

351870.47

164.95

ref (1.00)

 

ref (1.00)

 

APD

7,742

5,671

13828.8

410.09

2.1 (2.04–2.16)

< 0.0001

1.72 (1.67–1.77)

< 0.0001

Psychiatric (-)c

2,303

31,815

219,860.5

144.71

ref (1.00)

 

ref (1.00)

 

Psychiatric (+)c

5,439

32,207

146,440.4

219.93

0.99 (0.94–1.05)

0.7420

0.93 (0.81–1.07)

0.3072

Delirium d

249

193

381.69

505.65

ref (1.00)

 

ref (1.00)

 

Excluding delirium d

7,880

5,789

14,048.79

412.06

0.97(0.89–1.02)

0.0862

0.96(0.88–1.01)

0.0772

Prescription Timec

    

Pre RT c

2061

1421

3705.66

383.47

ref (1.00)

 

ref (1.00)

 

During RT c

6068

4064

9481.18

428.64

1.13(1.06–1.20)

0.0001

0.97(0.90–1.06)

0.5520

Non after RT c

5451

4064

9481.18

428.64

ref (1.00)

 

ref (1.00)

 

After RT c

2990

497

1243.63

399.64

0.96(0.88–1.06)

0.4099

0.94(0.86–1.03)

0.2103

Prescription durationc

    

< 3 month c

7542

5580

13286.87

419.96

ref (1.00)

 

ref (1.00)

 

≥ 3 month c

587

402

1143.61

351.52

0.84 (0.76–0.93)

0.0005

0.90 (0.80-1.00)

0.045

Prescription dosec

    

Low dose c

7,299

5,384

12887.47

417.77

ref (1.00)

 

ref (1.00)

 

High dose c

443

287

941.34

304.88

0.78 (0.69–0.87)

< 0.0001

0.9 (0.8–1.02)

0.1026

  1. HR: Hazard ratios, RT: radiotherapy, CCRT: concomitant chemo-radiotherapy, APD: antipsychotic drugs, Adjusted HR: Survival analysis adjusted for Sex, Age, CCI and medical history and psychiatric history, a: in the patients who used APDs during RT, b: in patients who used APDs during RT with psychiatric history, c: in the patients who used APDs during CCRT, d: in patients who used APDs during CCRT with psychiatric history